search
Back to results

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Primary Purpose

Multiple Myeloma

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
REGN5458
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Multiple Myeloma focused on measuring Relapsed, Refractory

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)

Inclusion Criteria:

-

Exclusion Criteria:

-

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    December 9, 2021
    Last Updated
    June 27, 2023
    Sponsor
    Regeneron Pharmaceuticals
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05164250
    Brief Title
    Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Regeneron Pharmaceuticals

    4. Oversight

    5. Study Description

    Brief Summary
    Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
    Detailed Description
    Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Multiple Myeloma
    Keywords
    Relapsed, Refractory

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    REGN5458
    Other Intervention Name(s)
    BCMAxCD3, linvoseltamab

    10. Eligibility

    Eligibility Criteria
    Inclusion Criteria: - Exclusion Criteria: -
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Requests for compassionate use must be initiated by a treating physician. Physicians should contact
    Phone
    844-734-6643
    Email
    CompassionateUserRequests@regeneron.com

    12. IPD Sharing Statement

    Learn more about this trial

    Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

    We'll reach out to this number within 24 hrs